Skip to content Skip to footer
Our roadmap

A roadmap aiming for trials starting in Q1 2028

Our pipeline of drug programs is built around a single goal: delivering more precise and effective treatments to patients with serious diseases. By leveraging advanced technologies and a deep understanding of disease biology, we are developing a portfolio of targeted therapies designed to address critical unmet medical needs.

AGGRESSIVE PIPELINE

Our Pipeline

bioPROTAC

for dual use in diabetes and rhabdomyosarcoma (earliest first-in-human projected for Q1 2028)

ADC

ADC for pediatric DIPG and adult glioblastoma (IND-enabling studies begin Q4 2026)

ADC

ADC for pediatric hepatoblastoma and adult ovarian cancer (preclinical validation in progress)